🔬
You have used your free lookups for today
Upgrade to BiotechSigns Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.
Upgrade to Pro →← Back to screener
← Back to Screener
A

ABBV

AbbVie Inc
ImmunologyScore: 45/100📋 Full Profile
D
45
Analyst Summary
Verified 2026-04-11

AbbVie Inc (ABBV) is the lead sponsor of 200 active clinical trials listed on ClinicalTrials.gov[5], including 59 Phase 3[1], 48 Phase 2[2], 54 Phase 1[3], 6 Phase 4[4].

Trial NCT07032597[6] evaluates HArmonyCa Lidocaine Injectable Gel in Mid Face Volume Deficit with a target enrollment of 252 participants. Trial NCT06417775[7] evaluates Ubrogepant in Migraine with a target enrollment of 496 participants. Trial NCT04524611[8] evaluates Risankizumab in Crohn's Disease (CD) with a target enrollment of 527 participants.

ABBV has 3 Form 4 insider filings recorded at the SEC in the past 30 days[9].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. ClinicalTrials.gov (2026-04-11)
  5. ClinicalTrials.gov (2026-04-11)
  6. ClinicalTrials.gov · NCT07032597 (2025-08-14)
  7. ClinicalTrials.gov · NCT06417775 (2025-11-12)
  8. ClinicalTrials.gov · NCT04524611 (2026-04-07)
  9. SEC EDGAR · 0001551152 (2026-04-11)
Not financial advice. BiotechSigns scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.
No active signals for ABBV
Signal Summary
PDUFA0
Insider0
Clinical0
Data Sources
DilutionWatch○ PENDING
StonkWhisper○ PENDING
SEC EDGAR● LIVE
ClinicalTrials● LIVE
Yahoo Finance● LIVE